Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc (NASDAQ: MRNA) shares are up over 20% during the trading session on Friday. There are no direct news reports from the Company, so there are external factors at play.

Why Are Moderna Shares Trading Higher On Friday?

Shares of Moderna Inc (NASDAQ: MRNA) are up 25% this morning after the World Health Organisation called a special meeting to assess if the new heavily mutated Coronavirus variant could be more contagious or resistant than the delta variant. The stock is still down about 30% from its year-to-date high Moderna rose to prominence last […] The post Here's why Moderna shares are up 25% on Friday morning appeared first on Invezz.

Here's why Moderna shares are up 25% on Friday morning

Zoom Video

BioNTech SE

Pfizer

Peloton

The stock prices of vaccine makers Moderna and Pfizer surged Friday along with stay-at-home stocks like Zoom Video and Peloton.

Pandemic-related stocks from Zoom to Moderna jump as new coronavirus variant raises alarms and triggers lockdowns

It's a reversal of recent fortune for both companies.

Investors Turn to These 2 Nasdaq Stocks As the Market Falls

Fears over a new, heavily mutated variant of Covid-19 were sinking stock markets Friday.

Stay-at-Home Stocks Zoom, Peloton, and Moderna Surge

Teladoc

These two innovative healthcare stocks have the opportunity to continue changing medicine.

Better Buy: Teladoc vs. Moderna

It may determine the future of vaccine sales.

How This News May Represent a Crucial Test for Moderna and Pfizer

There's a good way for it to happen -- and a bad way.

Here's What It Would Take to Make Moderna Stock a Screaming Buy

United States Oil Fund LP

Vanguard Energy ETF

Energy Select Sector SPDR Fund

SPDR S&P Oil & Gas Exploration & Production ETF

Higher Thanksgiving demand should help oil and energy ETFs despite the renewed COVID fears.

Will Thanksgiving Help Oil & Energy ETFs Despite Covid Fears?

Investors have bigger things to worry about.

Does It Really Matter if the Government Helped Develop Moderna's Vaccine?

Moderna stock rallied by about 12% over the last week (five trading days) outperforming the S&P 500 which remained roughly flat over the same period. The recent gains come as the U.S. authorized booster vaccine shots for all adults, likely implying that Moderna's Covid-19 shot can be administered.

Covid Cases Are Rising Again. Buy Moderna Stock?

These might not be the only boosters that the FDA ultimately endorses.

Why FDA Boosters Authorization Could Be More Important for Pfizer and Moderna Than You Might Think

Moderna is expected to gain approval for booster shots for its COVID-19 vaccine.

Moderna ETFs to Rally on Positive COVID-19 Booster Shot News

Moderna Inc (NASDAQ: MRNA) is trading higher on continued strength Monday after the U.S. Food and Drug Administration last week authorized booster doses of the company's COVID-19 vaccine in the US for adults 18 and older. The booster can be used in all individuals 18 years and older who have completed a primary vaccination with any other authorized or approved COVID-19 vaccine.

Why Moderna Shares Continue To Climb Higher Today

The FDA authorizes booster doses of COVID-19 vaccines of PFE/BNTX and MRNA for use in all adults irrespective of the risk of exposure to coronavirus.

FDA Authorizes PFE & MRNA's COVID-19 Boosters for All Adults

A quiet monthslong legal fight between the U.S. National Institutes of Health and drugmaker Moderna over COVID-19 vaccine patents recently burst into public view. The outcome of the battle has important implications, not only for efforts to contain the pandemic but more broadly for drugs and vaccines that could be critical for future public health crises.

The Conversation: Moderna's patent dispute with the U.S. government gets at a crucial question: control over how the drug is used

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to Present at Upcoming Investor Conferences in December 2021

Moderna to Present at Upcoming Investor Conferences in December 2021

Novavax

Novavax has filed requests for the authorization of its coronavirus vaccine candidate in several countries.

Will Novavax Be Worth as Much as Moderna by 2025?

Over 32 million Americans have already received a Covid-19 vaccine booster shot.

CDC Advisors Recommend Letting All U.S. Adults Take A Covid Booster Shot

Moderna updated FY21 revenue guidance that came in below consensus estimates. However, Moderna clarified that it was due to a delay in delivery to the US government.

Moderna Stock Forecast 2022: What To Consider Before Next Year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna's COVID-19 Vaccine

U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna's COVID-19 Vaccine

The CDC's director will need to accept the committee's recommendation, which she's expected to do soon.

CDC panel recommends COVID boosters for all adults

CDC Director Rochelle Walensky signed off on an independent panel's recommendation for all U.S. adults to be eligible for Pfizer and Moderna booster shots.

CDC panel unanimously endorses Pfizer and Moderna boosters for all U.S. adults

Republicans are disproportionately likely to say they won't get the third shot.

FDA Authorizes Booster Shots For All Adults — But 20% Of Vaccinated Americans Might Not Get One, Polls Show

Moderna Inc (NASDAQ:MRNA) shares are trading higher Friday after the FDA authorized its booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older. The company may also be moving on continued momentum after an announcement yesterday stating it filed for authorization of its COVID-19 vaccine, a 50 microgram two-dose series of SPIKEVAX, with Health Canada to include children ages six to 11.

News for Moderna Stock (MRNA)